title: Long-term treatment of macroprolactinomas with CV 205-502.
abstract: The long-term efficacy and tolerability of CV 205-502, a non-ergot dopamine agonist with D-2 receptor affinity, were studied for up to 36 months in 16 patients with macroprolactinomas. Prolactin values were reduced in all cases, becoming either normalized or suppressed in 12. The pituitary tumor size was reduced in the 13 patients with an obvious tumor and visual function normalized in all six patients with initial defects. Concomitantly we observed improvement in gonadal function, galactorrhea, headache, libido and general well-being. Adverse reactions were experienced by 15 patients during dosage increment and caused one patient to discontinue the medication. Seven patients had persistent adverse effects which prohibited a dosage increase of CV 205-502, sufficient to normalize PRL levels in three. Two patients experienced serious adverse events, causing the discontinuation of treatment in one case. In eight patients treatment with CV 205-502 and bromocriptine could be compared. Three patients responded better to CV 205-502 than to bromocriptine treatment. Only one patient preferred bromocriptine to CV 205-502 for long-term treatment. We conclude that CV 205-502 is an effective and in most cases well-tolerated treatment for patients with macroprolactinomas. CV 205-502 is preferable to bromocriptine as an initial treatment and should also be tried in patients where treatment with bromocriptine has failed.
authors.affiliation: Medical Department B, Rikshospitalet, National Hospital, Oslo, Norway.
authors.forename: A
authors.initials: A
authors.lastname: Kvistborg
authors.forename: J
authors.initials: J
authors.lastname: Halse
authors.forename: S
authors.initials: S
authors.lastname: Bakke
authors.forename: T
authors.initials: T
authors.lastname: Bjøro
authors.forename: E
authors.initials: E
authors.lastname: Hansen
authors.forename: O
authors.initials: O
authors.lastname: Djøseland
authors.forename: J
authors.initials: J
authors.lastname: Brownell
authors.forename: J
authors.initials: J
authors.lastname: Jervell
mesh_terms: D000328:Adult; D000634:Aminoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004361:Drug Tolerance; D007172:Erectile Dysfunction / Q000188:drug therapy; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007989:Libido / Q000187:drug effects; D008137:Longitudinal Studies; D008297:Male; D008598:Menstruation / Q000187:drug effects; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000097:blood / Q000188:drug therapy*; D011863:Radioimmunoassay; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000097:blood; D014794:Visual Fields / Q000187:drug effects
chemical_list: D000634:Aminoquinolines; D015259:Dopamine Agents; D012738:Sex Hormone-Binding Globulin; D001971:Bromocriptine; D013739:Testosterone; D004958:Estradiol; C046650:quinagolide; D011388:Prolactin